Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jul 3:19:e10.
doi: 10.15420/icr.2021.29. eCollection 2024.

Transcatheter Treatment Options for Functional Mitral Regurgitation: Which Device for Which Patients?

Stephanie K Tom  1 , Kanika Kalra  1 , Emily Perdoncin  2 , Andy Tully  1 , Chandan M Devireddy  2 , Errol Inci  2 , Adam Greenbaum  2 , Kendra J Grubb  1
Affiliations
Review

Transcatheter Treatment Options for Functional Mitral Regurgitation: Which Device for Which Patients?

Stephanie K Tom et al. Interv Cardiol. .

Abstract

Mitral regurgitation is the most common valvular disease in the developed world, with approximately 24.2 million people being affected worldwide and a higher prevalence in older age groups. Surgical correction of degenerative mitral regurgitation is the standard of care and can restore cardiac function and provide a lasting result, especially when the mitral valve can be repaired. Secondary mitral regurgitation, or functional mitral regurgitation (FMR), describes atrial or ventricular factors leading to poor coaptation of an otherwise non-diseased valve. For FMR, traditional surgery has not produced the same level of benefit. Transcatheter mitral repair and replacement techniques that mimic surgical correction are under investigation. Transcatheter edge-to-edge repair is the only approved catheter-based therapy for FMR in the US. Here, the transcatheter treatment options for FMR are reviewed.

Keywords: Functional mitral regurgitation; transcatheter edge-to-edge repair; transcatheter mitral valve replacement.

PubMed Disclaimer

Conflict of interest statement

Disclosure: AG is a consultant for Edwards Lifesciences. KJG is a consultant for Abbott, Boston Scientific, Medtronic, Edwards Lifesciences and 4C Medical. CMD is a paid consultant for Edwards Lifesciences, Medtronic, ReCor Medical and Shockwave Medical. All other authors have no conflicts of interest to declare.

Figures

Figure 1:
Figure 1:. Functional Mitral Regurgitation: Which Device for Which Patient?
See this image and copyright information in PMC

References

    1. Coffey S, Cairns BJ, Iung B. The modern epidemiology of heart valve disease. Heart. 2016;102:75–85. doi: 10.1136/heartjnl-2014-307020. - DOI - PubMed
    1. Peters AS, Duggan JP, Trachiotis GD, Antevil JL. Epidemiology of valvular heart disease. Surg Clin North Am. 2022;102:517–28. doi: 10.1016/j.suc.2022.01.008. - DOI - PubMed
    1. Roth GA, Mensah GA, Johnson CO et al. Global burden of cardiovascular diseases and risk factors, 1990–2019: update from the GBD 2019 study. J Am Coll Cardiol. 2020;76:2982–3021. doi: 10.1016/j.jacc.2020.11.010. - DOI - PMC - PubMed
    1. de Marchena E, Badiye A, Robalino G et al. Respective prevalence of the different Carpentier classes of mitral regurgitation: a stepping stone for future therapeutic research and development. J Card Surg. 2011;26:385–92. doi: 10.1111/j.1540-8191.2011.01274.x. - DOI - PubMed
    1. Levine RA, Schwammenthal E. Ischemic mitral regurgitation on the threshold of a solution: from paradoxes to unifying concepts. Circulation. 2005;112:745–58. doi: 10.1161/CIRCULATIONAHA.104.486720. - DOI - PubMed

LinkOut - more resources